Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Other Working Capital Changes (2017 - 2025)

Cue Biopharma's Other Working Capital Changes history spans 9 years, with the latest figure at $764000.0 for Q3 2025.

  • For Q3 2025, Other Working Capital Changes rose 133.09% year-over-year to $764000.0; the TTM value through Sep 2025 reached $2.6 million, up 148.53%, while the annual FY2024 figure was -$2.0 million, 28.73% up from the prior year.
  • Other Working Capital Changes for Q3 2025 was $764000.0 at Cue Biopharma, up from $467000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.7 million in Q3 2023 and bottomed at -$3.1 million in Q4 2023.
  • The 5-year median for Other Working Capital Changes is $394500.0 (2024), against an average of -$237111.1.
  • The largest annual shift saw Other Working Capital Changes crashed 734.78% in 2021 before it surged 245.48% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.1 million in 2021, then rose by 21.22% to -$880000.0 in 2022, then plummeted by 253.64% to -$3.1 million in 2023, then surged by 110.35% to $322000.0 in 2024, then surged by 137.27% to $764000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Other Working Capital Changes are $764000.0 (Q3 2025), $467000.0 (Q2 2025), and $1.1 million (Q1 2025).